• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TNFα 促进骨髓增殖性肿瘤中 JAK2V617F 阳性细胞的克隆扩增。

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

机构信息

Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.

出版信息

Blood. 2011 Dec 8;118(24):6392-8. doi: 10.1182/blood-2011-04-348144. Epub 2011 Aug 22.

DOI:10.1182/blood-2011-04-348144
PMID:21860020
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3236121/
Abstract

Proinflammatory cytokines such as TNFα are elevated in patients with myeloproliferative neoplasms (MPN), but their contribution to disease pathogenesis is unknown. Here we reveal a central role for TNFα in promoting clonal dominance of JAK2(V617F) expressing cells in MPN. We show that JAK2(V617F) kinase regulates TNFα expression in cell lines and primary MPN cells and TNFα expression is correlated with JAK2(V617F) allele burden. In clonogenic assays, normal controls show reduced colony formation in the presence of TNFα while colony formation by JAK2(V617F)-positive progenitor cells is resistant or stimulated by exposure to TNFα. Ectopic JAK2(V617F) expression confers TNFα resistance to normal murine progenitor cells and overcomes inherent TNFα hypersensitivity of Fanconi anemia complementation group C deficient progenitors. Lastly, absence of TNFα limits clonal expansion and attenuates disease in a murine model of JAK2(V617F)-positive MPN. Altogether our data are consistent with a model where JAK2(V617F) promotes clonal selection by conferring TNFα resistance to a preneoplastic TNFα sensitive cell, while simultaneously generating a TNFα-rich environment. Mutations that confer resistance to environmental stem cell stressors are a recognized mechanism of clonal selection and leukemogenesis in bone marrow failure syndromes and our data suggest that this mechanism is also critical to clonal selection in MPN.

摘要

促炎细胞因子如 TNFα 在骨髓增殖性肿瘤(MPN)患者中升高,但它们对疾病发病机制的贡献尚不清楚。在这里,我们揭示了 TNFα 在促进 JAK2(V617F) 表达细胞在 MPN 中克隆优势中的核心作用。我们表明,JAK2(V617F) 激酶调节细胞系和原发性 MPN 细胞中的 TNFα 表达,并且 TNFα 表达与 JAK2(V617F) 等位基因负担相关。在集落形成测定中,正常对照在 TNFα 存在的情况下显示出减少的集落形成,而 JAK2(V617F)-阳性祖细胞的集落形成对 TNFα 的暴露具有抗性或受到刺激。异位 JAK2(V617F) 表达赋予正常鼠祖细胞对 TNFα 的抗性,并克服了 Fanconi 贫血补体组 C 缺陷祖细胞固有的 TNFα 超敏性。最后,TNFα 的缺失限制了 JAK2(V617F) 阳性 MPN 小鼠模型中的克隆扩增并减轻了疾病。总之,我们的数据与以下模型一致:JAK2(V617F) 通过赋予对肿瘤坏死因子敏感的细胞对 TNFα 的抗性来促进克隆选择,同时产生富含 TNFα 的环境。赋予对环境干细胞应激物抗性的突变是骨髓衰竭综合征中克隆选择和白血病发生的公认机制,我们的数据表明,这种机制对于 MPN 中的克隆选择也至关重要。

相似文献

1
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.TNFα 促进骨髓增殖性肿瘤中 JAK2V617F 阳性细胞的克隆扩增。
Blood. 2011 Dec 8;118(24):6392-8. doi: 10.1182/blood-2011-04-348144. Epub 2011 Aug 22.
2
Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.鉴定出孤啡肽作为 JAK2 V617F 依赖性细胞因子产生和骨髓重构的扩增剂在骨髓增殖性肿瘤中的作用。
FASEB J. 2012 Feb;26(2):894-906. doi: 10.1096/fj.11-193078. Epub 2011 Nov 3.
3
Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2 against myeloproliferative neoplasms.发现并评价 ZT55,一种新型针对骨髓增殖性肿瘤的 JAK2 高选择性酪氨酸激酶抑制剂。
J Exp Clin Cancer Res. 2019 Feb 4;38(1):49. doi: 10.1186/s13046-019-1062-x.
4
JAK2 V617F-dependent upregulation of PU.1 expression in the peripheral blood of myeloproliferative neoplasm patients.JAK2 V617F 依赖性上调骨髓增殖性肿瘤患者外周血中 PU.1 的表达。
PLoS One. 2011;6(7):e22148. doi: 10.1371/journal.pone.0022148. Epub 2011 Jul 18.
5
The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.Jak2 抑制剂 G6 通过为骨髓提供显著的治疗效果,缓解了 Jak2-V617F 介导的骨髓增殖性肿瘤。
Neoplasia. 2011 Nov;13(11):1058-68. doi: 10.1593/neo.111112.
6
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.BMS-911543在JAK2 V617F骨髓增殖性肿瘤小鼠模型中的疗效有限。
Exp Hematol. 2015 Jul;43(7):537-45.e1-11. doi: 10.1016/j.exphem.2015.03.006. Epub 2015 Apr 24.
7
Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.促红细胞生成素受体中的三个酪氨酸残基对Janus激酶2 V617F突变体诱导的肿瘤发生至关重要。
J Biol Chem. 2017 Feb 3;292(5):1826-1846. doi: 10.1074/jbc.M116.749465. Epub 2016 Dec 20.
8
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.PIM抑制剂AZD1208与鲁索替尼协同作用,可诱导鲁索替尼敏感和耐药的JAK2-V617F驱动细胞凋亡,并抑制原发性骨髓增殖性肿瘤细胞的集落形成。
Oncotarget. 2015 Nov 24;6(37):40141-57. doi: 10.18632/oncotarget.5653.
9
Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.Ezh2缺失与JAK2-V617F协同作用,引发骨髓增殖性肿瘤并促进骨髓纤维化。
J Exp Med. 2016 Jul 25;213(8):1479-96. doi: 10.1084/jem.20151136. Epub 2016 Jul 11.
10
Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.酪氨酸磷酸化的 SOCS3 负调控由骨髓增殖性肿瘤相关 JAK2 V617F 突变体介导的细胞转化。
Cytokine. 2019 Nov;123:154753. doi: 10.1016/j.cyto.2019.154753. Epub 2019 Jun 27.

引用本文的文献

1
Inflammatory signaling in the pathogenesis of acute myeloid leukemia.急性髓系白血病发病机制中的炎症信号传导
Hemasphere. 2025 Aug 13;9(8):e70188. doi: 10.1002/hem3.70188. eCollection 2025 Aug.
2
Activation of integrin signaling up-regulates pro-inflammatory cytokines in JAK2-V617F positive hematopoietic cells.整合素信号的激活上调JAK2-V617F阳性造血细胞中的促炎细胞因子。
Cell Commun Signal. 2025 Aug 11;23(1):368. doi: 10.1186/s12964-025-02358-x.
3
Monocyte Involvement in the Pathogenesis of Myeloproliferative Neoplasms.单核细胞在骨髓增殖性肿瘤发病机制中的作用
Int J Mol Sci. 2025 Jul 3;26(13):6422. doi: 10.3390/ijms26136422.
4
TNF-α impairs platelet function by inhibiting autophagy and disrupting metabolism via syntaxin 17 downregulation.肿瘤坏死因子-α通过抑制自噬和经由 syntaxin 17 下调破坏代谢来损害血小板功能。
J Clin Invest. 2025 Jun 10;135(15). doi: 10.1172/JCI186065. eCollection 2025 Aug 1.
5
Efficacy of JAK1/2 inhibition in murine myeloproliferative neoplasms is not mediated by targeting oncogenic signaling.JAK1/2抑制在小鼠骨髓增殖性肿瘤中的疗效并非通过靶向致癌信号传导介导。
Nat Commun. 2025 May 24;16(1):4833. doi: 10.1038/s41467-025-60019-6.
6
Malignant JAK-signaling: at the interface of inflammation and malignant transformation.恶性JAK信号传导:炎症与恶性转化的交汇点
Leukemia. 2025 May;39(5):1011-1030. doi: 10.1038/s41375-025-02569-8. Epub 2025 Mar 26.
7
The Emerging Role of CD8 T Cells in Shaping Treatment Outcomes of Patients with MDS and AML.CD8 T细胞在塑造骨髓增生异常综合征和急性髓系白血病患者治疗结局中的新作用
Cancers (Basel). 2025 Feb 22;17(5):749. doi: 10.3390/cancers17050749.
8
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia.不成熟粒细胞分泌的 CXCL8 抑制慢性粒单核细胞白血病中的 WT 造血。
J Clin Invest. 2024 Sep 17;134(22):e180738. doi: 10.1172/JCI180738.
9
New approaches to standard of care in early-phase myeloproliferative neoplasms: can interferon-α alter the natural history of the disease?早期骨髓增殖性肿瘤护理标准的新方法:α干扰素能否改变疾病的自然病程?
Haematologica. 2025 Apr 1;110(4):850-862. doi: 10.3324/haematol.2023.283958. Epub 2024 Oct 24.
10
A proinflammatory stem cell niche drives myelofibrosis through a targetable galectin-1 axis.促炎干细胞龛通过可靶向的半乳糖凝集素-1 轴驱动骨髓纤维化。
Sci Transl Med. 2024 Oct 9;16(768):eadj7552. doi: 10.1126/scitranslmed.adj7552.

本文引用的文献

1
The stem cell fitness landscape and pathways of molecular leukemogenesis.干细胞适应性景观与分子白血病发生途径。
Front Biosci (Schol Ed). 2011 Jan 1;3(2):487-500. doi: 10.2741/s167.
2
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.生理 Jak2V617F 表达导致致命的骨髓增殖性肿瘤,并对造血干/祖细胞产生不同的影响。
Cancer Cell. 2010 Jun 15;17(6):584-96. doi: 10.1016/j.ccr.2010.05.015.
3
JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia.JAK2 V617F 损害条件性敲入 JAK2 V617F 阳性原发性血小板增多症小鼠模型中造血干细胞的功能。
Blood. 2010 Sep 2;116(9):1528-38. doi: 10.1182/blood-2009-12-259747. Epub 2010 May 20.
4
Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.新型抑制衔接蛋白 LNK 突变驱动骨髓增殖性肿瘤患者的 JAK-STAT 信号通路。
Blood. 2010 Aug 12;116(6):988-92. doi: 10.1182/blood-2010-02-270108. Epub 2010 Apr 19.
5
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.CYT387,一种新型 JAK2 抑制剂,可诱导血液学反应并使小鼠骨髓增殖性肿瘤中的炎症细胞因子恢复正常。
Blood. 2010 Jun 24;115(25):5232-40. doi: 10.1182/blood-2009-05-223727. Epub 2010 Apr 12.
6
TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells.TLR8 依赖性 TNF-α 在范可尼贫血症 C 组细胞中的过度表达。
Blood. 2009 Dec 17;114(26):5290-8. doi: 10.1182/blood-2009-05-222414. Epub 2009 Oct 22.
7
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.CYT387,一种选择性JAK1/JAK2抑制剂:激酶选择性的体外评估以及使用真性红细胞增多症患者的细胞系和原代细胞进行的临床前研究。
Leukemia. 2009 Aug;23(8):1441-5. doi: 10.1038/leu.2009.50. Epub 2009 Mar 19.
8
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms.JAK2单倍型是骨髓增殖性肿瘤发生的主要危险因素。
Nat Genet. 2009 Apr;41(4):446-9. doi: 10.1038/ng.334. Epub 2009 Mar 15.
9
JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.骨髓增殖性肿瘤中的JAK2和MPL突变:发现与科学
Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28.
10
TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells.肿瘤坏死因子-α在体外诱导范科尼贫血C组小鼠干细胞发生白血病克隆进化。
J Clin Invest. 2007 Nov;117(11):3283-95. doi: 10.1172/JCI31772.